|Expense Ratio (net)||1.20%|
|Morningstar Risk Rating||High|
|Last Cap Gain||0.00|
|Inception Date||Feb 2, 2010|
|Average for Category||N/A|
BOSTON, Jan. 30, 2018 /PRNewswire/ -- The Eventide Gilead Fund (ETILX) and the Eventide Healthcare & Life Sciences Fund (ETIHX) were both named as "Category Kings" by the Wall Street Journal for 2017. Both Funds are managed by Eventide Asset Management, LLC, a Boston-based registered investment adviser that designs investments for performance and a better world. Eventide CEO Robin John commented, "We are pleased with the results, yet more importantly, proud of how they were achieved.
BOSTON, July 31, 2017 /PRNewswire/ -- The Eventide Gilead Fund (NASDAQ: ETGLX, NASDAQ: ETAGX, NASDAQ: ETCGX, NASDAQ: ETILX) received a Wall Street Journal "Category King" on June 30, 2017. The award recognizes the top 10 funds in each equity category for one-year total return performance.